YD Bio Ltd (YDES) FinancialsYDESYD Bio Ltd

Evaluating the bottom line, YD Bio Ltd maintains a gross margin of 30.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -381.58%, while the net margin is 791.55%. These profitability ratios, combined with a Return on Equity (ROE) of 6.40%, provide a clear picture of how effectively YDES converts its operational activities into shareholder value.

In the context of the broader market, YDES competes directly with industry leaders such as NPCE and RCEL. With a market capitalization of $350.67M, it holds a significant position in the sector. When comparing efficiency, YDES's gross margin of 30.69% stands against NPCE's 82.83% and RCEL's 82.17%. Such benchmarking helps identify whether YD Bio Ltd is trading at a premium or discount relative to its financial performance.

Yd Bio Ltd has a gross margin of 30.69% projected for Q2 2026, which is relatively stable, but the company has faced significant losses with a net margin of -1392.61% in Q4 2025. The current ratio is strong at 5.23, indicating good short-term financial health.